{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:05:56Z","timestamp":1790622356528,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":120,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:sec><jats:title>Background and purpose:<\/jats:title><jats:p>The beneficial effect of 5\u2010HT<jats:sub>6<\/jats:sub> receptor antagonism in cognition remains controversial. This study has been undertaken to reassess the cognition enhancing properties of acute vs subchronic treatment with the selective 5\u2010HT<jats:sub>6<\/jats:sub> receptor antagonist SB\u2010271046 in unimpaired rats, as well as against scopolamine (cholinergic\u2010) or MK\u2010801 (glutamatergic\u2010mediated) deficits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental approach:<\/jats:title><jats:p>The Morris water maze was used, measuring behaviour acquisition and retention, and swim speed. Other behavioural measures included yawning and motor activity. SB\u2010271046 was given acutely before each trial or subchronically for 7 days before the trials. The AChE inhibitor galanthamine was also used alone or in combination with SB\u2010271046.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key results:<\/jats:title><jats:p>Subchronic treatment with SB\u2010271046 improved acquisition in the Morris water maze, while the acute treatment only improved retention. Neither acute nor subchronic SB\u2010271046 treatment reversed scopolamine\u2010induced learning deficits. MK\u2010801 induced learning impairment associated with a behavioural syndrome, reversed by acute, but not subchronic, SB\u2010271046 treatment. Interestingly, combined treatment with galanthamine and SB\u2010271046 reversed the scopolamine\u2010 or MK\u2010801\u2010induced learning impairments. Subchronic treatment with SB\u2010271046 did not modify motor activity or the increased number of yawns, a cholinergic\u2010mediated behaviour, induced by single administration of SB\u2010271046.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and implications:<\/jats:title><jats:p>These data suggest a potential therapeutic role of 5\u2010HT<jats:sub>6<\/jats:sub> receptor antagonists such as SB\u2010271046, alone or in combination with galanthamine, in the treatment of cognitive dysfunction, such as those seen in Alzheimer's disease and schizophrenia.<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2008) <jats:bold>155<\/jats:bold>, 434\u2013440; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/bjp.2008.281\">10.1038\/bjp.2008.281<\/jats:ext-link>; published online 14 July 2008<\/jats:p><\/jats:sec>","DOI":"10.1038\/bjp.2008.281","type":"journal-article","created":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T09:58:16Z","timestamp":1216029496000},"page":"434-440","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Effects of 5\u2010HT<sub>6<\/sub> receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat"],"prefix":"10.1111","volume":"155","author":[{"given":"B","family":"Marcos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T T","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Gil\u2010Bea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00116-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00180-9"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702445"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200001170-00034"},{"key":"e_1_2_7_6_1","first-page":"19","article-title":"Characterization of the selective 5\u2010HT6 receptor antagonist SB\u2010271046","volume":"776","author":"Callahan PM","year":"2004","journal-title":"Soc Neurosci Meet"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(93)90483-2"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00265-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703288"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1467-1"},{"key":"e_1_2_7_11_1","first-page":"369","article-title":"Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy","volume":"31","author":"Ferreri F","year":"2006","journal-title":"J Psychi Neurosci"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(95)00002-E"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300332"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(84)90084-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2004.11.002"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00043-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.6.1295"},{"key":"e_1_2_7_18_1","first-page":"7","article-title":"Characterization of SB\u2010399885, a potent and selective 5\u2010HT6 receptor antagonist","volume":"576","author":"Hirst WD","year":"2003","journal-title":"Soc Neurosci Meet"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.03.012"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300777"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.056002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90250-L"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.05003.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033376"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(00)00316-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2006.11.048"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.10.002"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.05.001"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(84)90007-4"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2005.05.005"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)00568-4"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm021085c"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100840"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1683-8"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703457"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026023393877"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.04.006"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00400-6"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701851"},{"key":"e_1_2_7_40_1","first-page":"31","article-title":"Cognitive function in schizophrenic patients","volume":"11","author":"Tollefson GD","year":"1996","journal-title":"J Clin Psychi"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199903170-00023"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb11381.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00056-9"},{"key":"e_1_2_7_44_1","first-page":"59","article-title":"5\u2010ht6 receptors","volume":"3","author":"Woolley ML","year":"2004","journal-title":"Curr Drug Targets"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fbjp.2008.281","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fbjp.2008.281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/bjp.2008.281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:34:45Z","timestamp":1697110485000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/bjp.2008.281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1038\/bjp.2008.281"],"URL":"https:\/\/doi.org\/10.1038\/bjp.2008.281","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}